lactic acid has been researched along with Prostatic Hyperplasia in 6 studies
Lactic Acid: A normal intermediate in the fermentation (oxidation, metabolism) of sugar. The concentrated form is used internally to prevent gastrointestinal fermentation. (From Stedman, 26th ed)
2-hydroxypropanoic acid : A 2-hydroxy monocarboxylic acid that is propanoic acid in which one of the alpha-hydrogens is replaced by a hydroxy group.
Prostatic Hyperplasia: Increase in constituent cells in the PROSTATE, leading to enlargement of the organ (hypertrophy) and adverse impact on the lower urinary tract function. This can be caused by increased rate of cell proliferation, reduced rate of cell death, or both.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To assess whether patients in acute urinary retention from benign prostatic enlargement can be treated with a combined therapy comprising finasteride and a bioabsorbable self-reinforced poly L-lactic acid (SR-PLLA) urethral stent." | 9.09 | A double-blind, randomized, placebo-controlled pilot study to investigate the effects of finasteride combined with a biodegradable self-reinforced poly L-lactic acid spiral stent in patients with urinary retention caused by bladder outlet obstruction from ( Hellström, P; Isotalo, T; Perttilä, I; Talja, M; Tammela, TL; Törmälä, P; Välimaa, T, 2001) |
| "To evaluate, in a pilot study, the efficacy and safety of combining a braided poly(lactic-co-glycolic acid) (PLGA, a copolymer of l-lactide and glycolide) urethral stent and dutasteride in the treatment of acute urinary retention (AUR) due to benign prostatic enlargement (BPE)." | 7.75 | Biodegradable braided poly(lactic-co-glycolic acid) urethral stent combined with dutasteride in the treatment of acute urinary retention due to benign prostatic enlargement: a pilot study. ( Hänninen, V; Isotalo, T; Juuti, H; Kellomäki, M; Kotsar, A; Leppiniemi, J; Mikkonen, J; Talja, M; Tammela, TL, 2009) |
| "To assess whether patients with acute urinary retention from benign prostatic enlargement can be treated with a combined therapy comprising a bioabsorbable self-reinforced poly L-lactic acid (SR-PLLA) urethral stent and finasteride." | 7.70 | A pilot study of a bioabsorbable self-reinforced poly L-lactic acid urethral stent combined with finasteride in the treatment of acute urinary retention from benign prostatic enlargement. ( Isotalo, T; Talja, M; Tammela, TL; Törmälä, P; Välimaa, T, 2000) |
| "To assess whether patients in acute urinary retention from benign prostatic enlargement can be treated with a combined therapy comprising finasteride and a bioabsorbable self-reinforced poly L-lactic acid (SR-PLLA) urethral stent." | 5.09 | A double-blind, randomized, placebo-controlled pilot study to investigate the effects of finasteride combined with a biodegradable self-reinforced poly L-lactic acid spiral stent in patients with urinary retention caused by bladder outlet obstruction from ( Hellström, P; Isotalo, T; Perttilä, I; Talja, M; Tammela, TL; Törmälä, P; Välimaa, T, 2001) |
| "This study aimed to use the biocompatibility features of the biodegradable polymers to prepare depot injectable finasteride (FIN) microspheres for the treatment of benign prostatic hyperplasia." | 3.83 | Optimisation of microstructured biodegradable finasteride formulation for depot parenteral application. ( Ahmed, OA; Hussein, AK; Mady, FM, 2016) |
| "To evaluate, in a pilot study, the efficacy and safety of combining a braided poly(lactic-co-glycolic acid) (PLGA, a copolymer of l-lactide and glycolide) urethral stent and dutasteride in the treatment of acute urinary retention (AUR) due to benign prostatic enlargement (BPE)." | 3.75 | Biodegradable braided poly(lactic-co-glycolic acid) urethral stent combined with dutasteride in the treatment of acute urinary retention due to benign prostatic enlargement: a pilot study. ( Hänninen, V; Isotalo, T; Juuti, H; Kellomäki, M; Kotsar, A; Leppiniemi, J; Mikkonen, J; Talja, M; Tammela, TL, 2009) |
| "To assess whether patients with acute urinary retention from benign prostatic enlargement can be treated with a combined therapy comprising a bioabsorbable self-reinforced poly L-lactic acid (SR-PLLA) urethral stent and finasteride." | 3.70 | A pilot study of a bioabsorbable self-reinforced poly L-lactic acid urethral stent combined with finasteride in the treatment of acute urinary retention from benign prostatic enlargement. ( Isotalo, T; Talja, M; Tammela, TL; Törmälä, P; Välimaa, T, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (16.67) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sun, SC | 1 |
| Zhao, H | 1 |
| Liu, R | 1 |
| Wang, BL | 1 |
| Liu, YQ | 1 |
| Zhao, Y | 1 |
| Shi, ZD | 1 |
| Ahmed, OA | 1 |
| Hussein, AK | 1 |
| Mady, FM | 1 |
| Kotsar, A | 1 |
| Isotalo, T | 3 |
| Juuti, H | 1 |
| Mikkonen, J | 1 |
| Leppiniemi, J | 1 |
| Hänninen, V | 1 |
| Kellomäki, M | 1 |
| Talja, M | 3 |
| Tammela, TL | 3 |
| Välimaa, T | 2 |
| Törmälä, P | 2 |
| Hellström, P | 1 |
| Perttilä, I | 1 |
| Dimberg, M | 1 |
| Allgén, LG | 1 |
| Norlén, H | 1 |
1 trial available for lactic acid and Prostatic Hyperplasia
| Article | Year |
|---|---|
A double-blind, randomized, placebo-controlled pilot study to investigate the effects of finasteride combined with a biodegradable self-reinforced poly L-lactic acid spiral stent in patients with urinary retention caused by bladder outlet obstruction from
Topics: Absorbable Implants; Aged; Aged, 80 and over; Combined Modality Therapy; Double-Blind Method; Enzyme | 2001 |
5 other studies available for lactic acid and Prostatic Hyperplasia
| Article | Year |
|---|---|
[Expression of long non-coding RNA H19 in prostate cancer and its effect on the proliferation and glycometabolism of human prostate cancer cells].
Topics: Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation, Neoplastic; Glucose; Humans; Lacti | 2017 |
Optimisation of microstructured biodegradable finasteride formulation for depot parenteral application.
Topics: Animals; Biocompatible Materials; Caproates; Delayed-Action Preparations; Drug Compounding; Finaster | 2016 |
Biodegradable braided poly(lactic-co-glycolic acid) urethral stent combined with dutasteride in the treatment of acute urinary retention due to benign prostatic enlargement: a pilot study.
Topics: Acute Disease; Aged; Aged, 80 and over; Azasteroids; Biocompatible Materials; Dutasteride; Enzyme In | 2009 |
A pilot study of a bioabsorbable self-reinforced poly L-lactic acid urethral stent combined with finasteride in the treatment of acute urinary retention from benign prostatic enlargement.
Topics: Acute Disease; Aged; Aged, 80 and over; Ambulatory Care; Combined Modality Therapy; Enzyme Inhibitor | 2000 |
Absence of lactate accumulation on transurethral resection of the prostate using 2.5% sorbitol solution as an irrigating fluid.
Topics: Blood Glucose; Fructose; Humans; Lactates; Lactic Acid; Male; Phosphates; Postoperative Complication | 1988 |